Cumberland is also focused on identifying earlier stage product candidates that have the potential to improve patient care.

Our majority-owned subsidiary, Cumberland Emerging Technologies (CET) is for just that purpose. We supplement our acquisition and late-stage development initiatives with CET’s early-stage drug development activities. CET represents a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, the state of Tennessee supported LaunchTN, and WinHealth Pharma. The mission of CET is to identify promising new biomedical products and advance them towards the marketplace.

At CET we have established a series of collaboration agreements with a select group of academic research institutions located across the mid-south region of the U.S. We work with our university partners to identify and establish arrangements for each new product candidate. We then team with the university scientific team to support product development and also identify opportunities to secure grant funding.